Search Results - "Hanselmann, Silvia"

Immediate Versus Deferred Hormonal Treatment for Patients With Prostate Cancer Who Are Not Suitable for Curative Local Treatment: Results of the Randomized Trial SAKK 08/88 by STUDER, Urs E, HAURI, Dieter, DIETRICH, Daniel, HANSELMANN, Silvia, CHOLLET, Dominique, LEISINGER, Hans-Jürg, GASSER, Thomas, SERIN, Edgar, TRINKLER, Felix B, TSCHOLL, Reto M, THALMANN, George N

“…To determine if immediate hormonal therapy is advantageous compared with deferred treatment in newly diagnosed asymptomatic prostate cancer patients who, for…”
Get full text

Phase II Study of Capecitabine and Oxaliplatin in First- and Second-Line Treatment of Advanced or Metastatic Colorectal Cancer by BORNER, Markus M, DIETRICH, Daniel, MÜLLER, Samuel, BRAUCHLI, Peter, CASTIGLIONE-GERTSCH, Monica, GOLDHIRSCH, Aron, ROTH, Arnaud D, STUPP, Roger, MORANT, Rudolf, HONEGGER, Hanspeter, WERNLI, Martin, HERRMANN, Richard, PESTALOZZI, Bernhard C, SALETTI, Piercarlo, HANSELMANN, Silvia

“…To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal…”
Get full text

Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02) by Leupin, Nicolas, Schuller, Jan C., Solenthaler, Max, Heim, Dominik, Rovo, Alicia, Beretta, Kurt, Gregor, Michael, Bargetzi, Mario J., Brauchli, Peter, Himmelmann, Andreas, Hanselmann, Silvia, Zenhäusern, Reinhard

“…This phase II trial investigated rituximab and cladribine in chronic lymphocytic leukemia. Four induction cycles, comprising cladribine (0.1 mg/kg/day days…”
Get full text

Effect of carboplatin on response and palliation in hormone-refractory prostate cancer by JUNGI, W. F, BERNHARD, J, HÜRNY, C, SCHMITZ, S.-F. H, HANSELMANN, S, GUSSET, H, PESTALOZZI, D, GOLDHIRSCH, A

“…To assess the efficacy of carboplatin in patients with hormone-refractory prostate cancer in terms of response rate and palliation, the Swiss Group for…”
Get full text

A Phase II study of oral idarubicin as a treatment for metastatic hormone‐refractory prostate carcinoma with special focus on prostate specific antigen doubling time by Schmid, Hans‐Peter, Maibach, Rudolf, Bernhard, Juerg, Hering, Franz, Hanselmann, Silvia, Gusset, Heidi, Morant, Rudolf, Pestalozzi, Dietegen, Castiglione, Monica

“…BACKGROUND Treatment of hormone‐refractory prostate carcinoma with chemotherapy is purely palliative, and reported response rates have been low. At the time…”
Get full text

Prostate specific antigen in as a dynamic model in advanced prostate cancer by Schmid, H P, Bernhard, J, Semjonow, A, Hanselmann, S, Hertle, L, Maibach, R

“…Prostate specific antigen doubling time (PSADT) is a prognostic factor after radical prostatectomy, radiation therapy, and hormonal therapy respectively for…”
Get more information